Third Quarter 2023
· Total revenue increased 29 per cent, +23 per cent at constant exchange rates, (CER)i, to
· Haematology revenue increased 25 per cent at CER to
· Immunology revenue increased 27 per cent at CER to
· The adjusted EBITA margini was 30 per cent, excluding items affecting comparability (IAC)ii. EBITA was
· Earnings per share (EPS) before dilution was
· The fully subscribed rights issue was completed in September and Sobi received approximately
Outlook 2023 - unchanged
· Revenue is anticipated to grow by a high single-digit percentage at CER
· EBITA margin adjustedi is anticipated to be at a low 30s percentage of revenue
"We are very pleased with Sobi's development during the quarter. Revenues increased for Haematology and Immunology 89 per cent of this was driven by our launch medicines, primarily in the US and internationally. This includes a strong contribution from Vonjo, added through our recent acquisition of
i. Alternative Performance Measures (APMs), see section APM for further information. |
ii. Items affecting comparability (IAC). |
iii. Comparatives have been adjusted to consider the bonus issue element in the rights issue, for which the final outcome was announced on 19 September.
|
Investors, analysts, and media are invited to participate in a conference call which will include a presentation of the results and a Q&A session on 30th October at
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.
To participate in the conference call, please use the following dial-in details:
For other countries, please get details here
Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, on
Acting Head of Communications and Investor Relations
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-q3-2023-report--strong-revenue-and-solid-performance,c3865068
https://mb.cision.com/Main/14266/3865068/2393153.pdf
(c) 2023 Cision. All rights reserved., source